Association of adiponectin multimers with Barrett's oesophagus - PubMed (original) (raw)

Association of adiponectin multimers with Barrett's oesophagus

J H Rubenstein et al. Gut. 2009 Dec.

Abstract

Objective: Barrett's oesophagus is associated with abdominal obesity. Adiponectin is a peptide that is secreted from adipocytes and circulates in three multimeric forms: low molecular weight (LMW), middle molecular weight (MMW), and high molecular weight (HMW). The anti-inflammatory effects of adiponectin are specific to individual multimers, with LMW being most anti-inflammatory. We postulated that circulating levels of adiponectin and its multimers would be associated with the risk of Barrett's oesophagus.

Design: Cross-sectional study.

Setting: Outpatient clinic in North Carolina, USA.

Patients: Cases of Barrett's oesophagus and controls undergoing upper endoscopy for gastro-oesophageal reflux disease (GORD).

Main outcome measures: Adjusted odds ratios of plasma adiponectin levels and its multimers for Barrett's oesophagus.

Results: There were 112 cases of Barrett's oesophagus and 199 GORD controls. Total adiponectin was not associated with Barrett's oesophagus (3(rd) tertile vs 1(st) tertile adjusted odds ratio (aOR) = 0.88; 95% confidence interval (CI) = 0.44 to 1.78). High levels of LMW adiponectin were associated with a decreased risk of Barrett's oesophagus (3(rd) tertile vs 1(st) tertile aOR = 0.33; 95% CI, 0.16 to 0.69), and a high LMW/total ratio appeared particularly inversely associated with Barrett's oesophagus (3(rd) tertile vs 1(st) tertile aOR = 0.27; 95% CI, 0.13 to 0.58).

Conclusions: High levels of LMW adiponectin are associated with a decreased risk of Barrett's oesophagus among patients with GORD. Further human studies are required to confirm these findings, and in vitro studies are needed to understand if there is a mechanism whereby adiponectin may affect Barrett's metaplasia.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None.

Figures

Figure 1

Figure 1

Box-plot of low molecular weight adiponectin. Each box-plot displays the 10th, 25th, 50th, 75th, and 90th percentiles of low molecular weight (LMW) adiponectin in cases of Barrett’s oesophagus and GORD controls, stratified by gender.

Figure 2

Figure 2

Box-plot of ratio of low molecular weight to total adiponectin. Each box-plot displays the 10th, 25th, 50th, 75th, and 90th percentiles of the ratio of low molecular weight (LMW) to total adiponectin in cases of Barrett’s oesophagus and GORD controls, stratified by gender.

Comment in

Similar articles

Cited by

References

    1. Corley DA, Kubo A, Levin TR, et al. Abdominal obesity and body mass index as risk factors for Barrett’s esophagus. Gastroenterology. 2007;133:34–41. quiz 311. - PubMed
    1. Edelstein ZR, Farrow DC, Bronner MP, et al. Central adiposity and risk of Barrett’s esophagus. Gastroenterology. 2007;133:403–11. - PubMed
    1. Lagergren J, Bergstrom R, Nyren O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med. 1999;130:883–90. - PubMed
    1. Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. New Engl J Med. 1999;340:825–31. - PubMed
    1. Lieberman DA, Oehlke M, Helfand M. Risk factors for Barrett’s esophagus in community-based practice. GORGE consortium. Gastroenterology Outcomes Research Group in Endoscopy. Am J Gastroenterol. 1997;92:1293–7. - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources